Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne

Background: Despite advances in acne therapy in recent years, treatment failure is common. Isotretinoin is the only drug that affects almost all factors in acne pathogenesis, but side-effects are common at the doses reported in published studies in the literature. The aim of this study was to invest...

Full description

Bibliographic Details
Main Authors: Abbas Rasi, Elham Behrangi, Masoumeh Rohaninasab, Zahra Mehr Nahad
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2014-01-01
Series:Advanced Biomedical Research
Subjects:
Online Access:http://www.advbiores.net/article.asp?issn=2277-9175;year=2014;volume=3;issue=1;spage=103;epage=103;aulast=Rasi
_version_ 1828437296102244352
author Abbas Rasi
Elham Behrangi
Masoumeh Rohaninasab
Zahra Mehr Nahad
author_facet Abbas Rasi
Elham Behrangi
Masoumeh Rohaninasab
Zahra Mehr Nahad
author_sort Abbas Rasi
collection DOAJ
description Background: Despite advances in acne therapy in recent years, treatment failure is common. Isotretinoin is the only drug that affects almost all factors in acne pathogenesis, but side-effects are common at the doses reported in published studies in the literature. The aim of this study was to investigate the efficacy of low daily dose isotretinoin in moderate to severe acne patients. The secondary objective was to measure the rate of relapse 5 years after the completion of therapy. Materials and Methods: In this retrospective, noncomparative study, 146 patients with moderate to severe scare prone acne. Treatment regimen consisted of isotretinoin, fixed 20 mg daily, and duration of treatment-based on the weight of patient, until total cumulative dose of 120 mg/kg of body weight is achieved. No topical or other systemic therapy was allowed during the trial. Liver function tests (serum glutamic-oxalocetic transaminase, serum glutamate pyruvate transaminase, direct and total bilirubin), and lipid profiles (total cholesterol, low-density lipoprotein, high-density lipoprotein, triglyceride) were evaluated for all patients, before the initiation of treatment and again after the 2 nd month of treatment. All data analyzed by Microsoft Office Excel 2007; in descriptive statics frequency and SPSS.18 software. Results: At the end of treatment course, (96.4%) demonstrated complete clearing of their acne, defined as no acne or occasional isolated lesions. In 5-year follow-up, relapse accrued in 11 (7.9%) of patients. All adverse effects were mild, and discontinuation of treatment was not necessary. Conclusion: Low dose isotretinoin was found to be a safe and effective choice for patients with moderate to severe scar prone acne vulgaris.
first_indexed 2024-12-10T19:42:54Z
format Article
id doaj.art-22a290043daf475abf007d94305b85ac
institution Directory Open Access Journal
issn 2277-9175
2277-9175
language English
last_indexed 2024-12-10T19:42:54Z
publishDate 2014-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Advanced Biomedical Research
spelling doaj.art-22a290043daf475abf007d94305b85ac2022-12-22T01:35:58ZengWolters Kluwer Medknow PublicationsAdvanced Biomedical Research2277-91752277-91752014-01-013110310310.4103/2277-9175.129693Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acneAbbas RasiElham BehrangiMasoumeh RohaninasabZahra Mehr NahadBackground: Despite advances in acne therapy in recent years, treatment failure is common. Isotretinoin is the only drug that affects almost all factors in acne pathogenesis, but side-effects are common at the doses reported in published studies in the literature. The aim of this study was to investigate the efficacy of low daily dose isotretinoin in moderate to severe acne patients. The secondary objective was to measure the rate of relapse 5 years after the completion of therapy. Materials and Methods: In this retrospective, noncomparative study, 146 patients with moderate to severe scare prone acne. Treatment regimen consisted of isotretinoin, fixed 20 mg daily, and duration of treatment-based on the weight of patient, until total cumulative dose of 120 mg/kg of body weight is achieved. No topical or other systemic therapy was allowed during the trial. Liver function tests (serum glutamic-oxalocetic transaminase, serum glutamate pyruvate transaminase, direct and total bilirubin), and lipid profiles (total cholesterol, low-density lipoprotein, high-density lipoprotein, triglyceride) were evaluated for all patients, before the initiation of treatment and again after the 2 nd month of treatment. All data analyzed by Microsoft Office Excel 2007; in descriptive statics frequency and SPSS.18 software. Results: At the end of treatment course, (96.4%) demonstrated complete clearing of their acne, defined as no acne or occasional isolated lesions. In 5-year follow-up, relapse accrued in 11 (7.9%) of patients. All adverse effects were mild, and discontinuation of treatment was not necessary. Conclusion: Low dose isotretinoin was found to be a safe and effective choice for patients with moderate to severe scar prone acne vulgaris.http://www.advbiores.net/article.asp?issn=2277-9175;year=2014;volume=3;issue=1;spage=103;epage=103;aulast=RasiAcneisotretinoinlow dose
spellingShingle Abbas Rasi
Elham Behrangi
Masoumeh Rohaninasab
Zahra Mehr Nahad
Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne
Advanced Biomedical Research
Acne
isotretinoin
low dose
title Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne
title_full Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne
title_fullStr Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne
title_full_unstemmed Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne
title_short Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne
title_sort efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne
topic Acne
isotretinoin
low dose
url http://www.advbiores.net/article.asp?issn=2277-9175;year=2014;volume=3;issue=1;spage=103;epage=103;aulast=Rasi
work_keys_str_mv AT abbasrasi efficacyoffixeddaily20mgofisotretinoininmoderatetoseverescarproneacne
AT elhambehrangi efficacyoffixeddaily20mgofisotretinoininmoderatetoseverescarproneacne
AT masoumehrohaninasab efficacyoffixeddaily20mgofisotretinoininmoderatetoseverescarproneacne
AT zahramehrnahad efficacyoffixeddaily20mgofisotretinoininmoderatetoseverescarproneacne